You just read:

Boston Biomedical Featured Seven Clinical Posters on Cancer Stem Cell Pathway Inhibitors Napabucasin and Amcasertib in Multiple Cancer Types at ASCO 2016

News provided by

Boston Biomedical, Inc.

07 Jun, 2016, 12:09 ET